Adam Woodrow - Paratek Pharmaceuticals Vice President and Chief Commercial Officer
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
President
Mr. Adam Woodrow is President and Chief Commercial Officer of Paratek Pharmaceuticals, Inc. From October 2009 until September 2014, Mr. Woodrow worked for Pfizer Inc. in various strategic and operational commercial roles. There, he had a worldwide responsibility for Global Strategic Marketing, New Business Development and Early Commercial Development for Pfizer Specialty Products. Mr. Woodrows portfolio included inflammation, antiinfectives, antifungals, hemophilia, endocrinology, neurology and rare diseases. Mr. Woodrows early commercial work focused on inflammation, neuroscience, hematology, renal and rare diseases. Mr. Woodrow joined Pfizer from Wyeth Pharmaceuticals, or Wyeth, where he was Vice President and Global Business Manager for Enbrel. In his 10 years at Wyeth, Mr. Woodrow held senior marketing and sales positions in the United States and in his native United Kingdom. Prior to joining Wyeth, Mr. Woodrow held sales and marketing positions with Bayer Pharmaceuticals. In his career in the pharmaceutical industry, Mr. Woodrow has worked with several nonprofit societies and organizations such as the Hemophilia Society, the Primary Immune Deficiency Society, the Prostate Cancer Support Association and has served on the board of the New York Chapter of the Arthritis Foundation since 2019.
| Age | 56 |
| Tenure | 5 years |
| Phone | 617 807 6600 |
| Web | https://paratekpharma.com |
Adam Woodrow Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Woodrow against Paratek Pharmaceuticals stock is an integral part of due diligence when investing in Paratek Pharmaceuticals. Adam Woodrow insider activity provides valuable insight into whether Paratek Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Paratek Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Paratek Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Woodrow over a year ago Disposition of 622284 shares by Adam Woodrow of Paratek Pharmaceuticals subject to Rule 16b-3 | ||
Adam Woodrow over a year ago Acquisition by Adam Woodrow of 98750 shares of Paratek Pharmaceuticals subject to Rule 16b-3 |
Paratek Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Paratek Pharmaceuticals currently holds 258.41 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Paratek Pharmaceuticals has a current ratio of 3.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Paratek Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 3 records | PRESIDENT Age | ||
| William Jones | Corvus Pharmaceuticals | 58 | |
| Bruce CFA | Equillium | 58 | |
| Erik Verner | Corvus Pharmaceuticals | 59 | |
Management Performance
| Return On Asset | -0.18 |
Paratek Pharmaceuticals Leadership Team
Elected by the shareholders, the Paratek Pharmaceuticals' board of directors comprises two types of representatives: Paratek Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paratek. The board's role is to monitor Paratek Pharmaceuticals' management team and ensure that shareholders' interests are well served. Paratek Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paratek Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Chairman | ||
| FACC FAHA, CEO Director | ||
| Karen McGrath, VP HR | ||
| Sarah Higgins, Interim Principal Financial Officer and Principal Accounting Officer | ||
| Ben Strain, VP CEO | ||
| William Haskel, Senior Vice President General Counsel, Corporate Secretary | ||
| Adam Woodrow, Vice President and Chief Commercial Officer | ||
| Jason Burdette, VP Operations | ||
| Randall Brenner, Chief Officer |
Paratek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paratek Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |